List_of_investigational_anxiolytics
This is a list of investigational anxiolytics, or anxiolytics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
- Riluzole sublingual (BHV-0223) – undefined mechanism of action
- TGFK08AA – 5-HT1A receptor modulator
- TGW00AA (FKW00GA) – 5-HT1A receptor agonist, 5-HT2A receptor antagonist
- Darigabat (PF-06372865) – GABAA receptor positive allosteric modulator
- JNJ-61393215 – orexin OX1 receptor antagonist
- 7-Oxoprasterone (7-keto-DHEA; HBL-9001) – "immunomodulator" / undefined mechanism of action
- BNC-210 (IW-2143) – "GABATooltip γ-aminobutyric acid modulator"[1] / undefined mechanism of action[2]
- Brexpiprazole (Lu AF41156, OPC-34712; Rexulti) – atypical antipsychotic / 5-HT1A, D2 and D3 receptor partial agonist and 5-HT2A, 5-HT2B, 5-HT7, α1-adrenergic, α2-adrenergic, and H1 receptor antagonist
- Iloperidone (HP-873, ILO-522; Fanapt, Fiapta, Zomaril) – atypical antipsychotic / 5-HT2A, 5-HT6, 5-HT7, D2, D3, D4, and α1-adrenergic receptor antagonist
- MDMA (Midomafetamine, 3,4-methylenedioxymethamphetamine, "ecstasy") – serotonin–norepinephrine–dopamine releasing agent and 5-HT1 and 5-HT2 receptor agonist – specifically under development as an aid to psychotherapy for post-traumatic stress disorder [3][4]
- NBTX-001 (Xenon) – NMDA receptor antagonist
- Pomaglumetad methionil (DB-103, LY-2140023) – mGluR2 and mGluR3 agonist
- Tianeptine oxalate/naloxone (TNX-601) – atypical μ-opioid receptor agonist
- Fasedienol (Aloradine; PH94B; 4-androstadienol) – vomeropherine / neurosteroid
- JNJ-42165279 – FAAH inhibitor[5][6]
- TGW00AA (FKW00GA) – 5-HT1A receptor agonist, 5-HT2A receptor antagonist
- AVN-101 – 5-HT6 receptor antagonist
- BNC-210 (IW-2143) – "GABA modulator"[1] / undefined mechanism of action / α7 subunit-containing nicotinic acetylcholine receptor antagonist[2]
- Deuterated etifoxine (GRX-917) – translocator protein (TSPO) agonist and GABAA receptor positive allosteric modulator[7]
- JNJ-42165279 – FAAH inhibitor
- JNJ-61393215 – orexin OX1 receptor antagonist
- MP-20X – CB1 and 5-HT1A receptor modulator
- SRX-246 – vasopressin V1A receptor antagonist
- Garakani A, Murrough JW, Iosifescu DV (2014). "Advances in Psychopharmacology for Anxiety Disorders". FOCUS. 12 (2): 152–162. doi:10.1176/appi.focus.12.2.152. ISSN 1541-4094.
- Doggrell, S. A. (2007). Novel drugs and products in neuroscience. Drugs of the Future, 32(11), 1007-1017. https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3853&p_IsPs=Y
- Philipps D (29 November 2016). "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients". The New York Times. Retrieved 1 June 2017.
- "JNJ 42165279 - AdisInsight". adisinsight.springer.com. Retrieved 2019-03-02.
- "A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder | Clinical Research Trial Listing ( Claustrophobia ) ( NCT02432703 )". www.centerwatch.com. Retrieved 2019-03-02.
- Rupprecht R, Pradhan AK, Kufner M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Puig X, Rupprecht C, Rammes G (December 2022). "Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options". Eur Arch Psychiatry Clin Neurosci. 273 (7): 1477–1487. doi:10.1007/s00406-022-01532-3. PMID 36574032. S2CID 255205221.